Surmodics

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Surmodics reports Q1 growth, FDA hurdles, and strategic partnerships

Surmodics navigates FDA challenges with the SurVeil application while focusing on cost-saving measures and revenue growth strategies for fiscal 2023.
The company's strong technology foundation, partnership with Abbott, and customer acceptance of key products position it well for future growth.
Despite challenges in FDA approval and spending reductions, Surmodics remains committed to innovation, regulatory compliance, and strategic partnerships.
Opportunities in product commercialization, revenue growth, and asset preservation offer avenues for overcoming challenges and driving long-term success.

Surmodics reports solid Q2 growth, navigates FDA approvals and revenue challenges

Surmodics shows strong performance in medical device sales and strategic objectives execution.
Challenges include In Vitro Diagnostics revenue decline and revised fiscal guidance.
Opportunities lie in significant sales growth projections and regulatory milestones.
Financial stability maintained through cash utilization plan and spending reduction measures.
Overall, Surmodics navigates growth and challenges with a focus on FDA approvals and revenue growth.

Surmodics excels in Q3 with robust revenue growth and strategic partnerships

Surmodics delivered exceptional Q3 results, driven by strong revenue growth and operational achievements, setting the stage for continued success.
The company's focus on cash flow generation, disciplined expense management, and strategic partnerships with Abbott bode well for future growth and profitability.
While facing challenges such as COVID-related impacts and revenue sharing negotiations, Surmodics remains poised to capitalize on opportunities for growth and innovation.
With a solid financial position, expanded revenue guidance, and readiness to support Abbott's commercial initiatives, Surmodics is well-positioned for a promising future.

Surmodics reports robust Q4 earnings, eyes growth amidst challenges

Surmodics delivered strong financial performance in Q4 2023 and fiscal 2023, driven by revenue growth and operational improvements.
While facing challenges such as competitive dynamics and projected losses in fiscal 2024, the company is well-positioned to capitalize on opportunities.
Strategic achievements, product advancements, and financial stability position Surmodics for continued growth and market success in the coming year.
Emphasis on innovation, market expansion, and cost management will be crucial for Surmodics to navigate challenges and leverage growth opportunities.

Surmodics reports robust Q1 growth, eyes new product launches

Surmodics' Q1 2024 performance reflects strong revenue growth, operational efficiency, and successful product launches, positioning the company for continued success in the medical device and diagnostics markets.
While challenges such as incremental expenses and pricing dynamics exist, Surmodics' focus on innovation, financial discipline, and market responsiveness presents opportunities for sustained growth and competitive advantage.
With a strategic outlook towards driving revenue growth, expanding product offerings, and optimizing expenses, Surmodics aims to navigate challenges and capitalize on opportunities for long-term success and market leadership.

Surmodics reports robust Q2 growth, eyes profitability amid challenges

Surmodics' Q2 2024 performance reflects revenue growth, improved profitability, and product innovation, underpinned by strong R&D focus and strategic partnerships.
While facing challenges in achieving profitability and providing clear guidance for fiscal 2025, the company remains optimistic about growth opportunities and market expansion.
With a focus on enhancing margins, expanding product offerings, and leveraging partnerships, Surmodics is poised for continued growth and innovation in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C. PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce™.

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.

SRDX Stock Down Despite FDA Clearance for Pounce XL System

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System is indicated for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature in vessels 5.5–10 mm in diameter, making it suitable for iliac, femoral, and other art.

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround

SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings

SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago.

SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Earnings--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary Total Revenue of $30.3 million, compared to $52.5 million in the prior-year period which included $24.6 million in license fee revenue recognized upon receipt of a $27.0 million milestone payment associated.

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surmodics, Inc. (NasdaqGS: SRDX) to GTCR. Under the terms of the proposed transaction, shareholders of Surmodics will receive $43.00 in cash for each share of Surmodics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideratio.

SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc . ( Nasdaq : SRDX ), relating to its proposed sale to GTCR LLC. Under the terms of the agreement, Surmodics, Inc. shareholders will receive $43.00 in cash per share of Surmodics stock they own.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDX

NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX

Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.

Surmodics (SRDX) Inks Group Purchasing Agreement With Premier

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems. “This is an exciting.

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?

Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.

Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M

NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquisition of the company by GTCR. Stockholders will receive $43.00 for each share of Surmodics stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.

Merck

Merck and Surmodics announced big takeover deals Wednesday, but Merck stock remained at a standstill as Surmodics stock rocketed.

Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals

MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. Click here to learn how to join the https://www.ademilaw.com/case/surmodics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surmodics, Inc. (NASDAQ: SRDX) to GTCR for $43.00 per share in cash is fair to Surmodics shareholders. Halper Sadeh encourages Surmodics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Surmodics and its board o.

SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the agreement, affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholde.

Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up

Surmodics, Inc. (NASDAQ:SRDX ) Q2 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Gary Maharaj - President and Chief Executive Officer Timothy Arens - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Joseph Conway - Needham & Company Jim Sidoti - Sidoti & Company Mike Petusky - Barrington Research Operator Welcome everyone to Surmodics' Second Quarter of Fiscal Year 2024 Earnings Call. Please note that this call is being webcast the webcast accessible through Investor Relations section of the Surmodics website at www.surmodics.com, where an audio replay will be archived for future reference.

News for Surmodics Stock (SRDX)